What are the recommended treatment guidelines for urge urinary incontinence?

Treatment Guidelines for Urge Urinary Incontinence

Start with bladder training as first-line therapy for urge urinary incontinence, and only add pharmacologic treatment if behavioral interventions fail—when medications are needed, choose based on side effect profile rather than efficacy since all agents work equally well. 1

First-Line Treatment: Behavioral Interventions

Bladder training should be offered to all women with urge incontinence as initial therapy (strong recommendation, moderate-quality evidence). 1 This approach is effective, has minimal adverse effects, and costs less than pharmacologic options. 1

Key Behavioral Strategies:

• Bladder training: Scheduled voiding with progressive interval increases to suppress urgency 1
• Fluid management: 25% reduction in fluid intake reduces frequency and urgency 1
• Caffeine reduction: Decreases voiding frequency 1
• Weight loss: In obese women, 8% weight loss reduces urgency incontinence episodes by 42% 1

Behavioral therapies are either equivalent to or superior to medications for reducing incontinence episodes, improving frequency, and enhancing quality of life. 1

Second-Line Treatment: Pharmacologic Therapy

Add medications only after bladder training proves unsuccessful. 1 All antimuscarinic and beta-3 agonist medications demonstrate similar efficacy with moderate benefit for achieving continence. 1

Medication Selection Strategy:

Base your choice on tolerability and adverse effect profile, NOT on efficacy differences, since all agents work equally well. 1

Preferred Initial Agents (lowest discontinuation rates):

• Darifenacin or tolterodine: Discontinuation rates similar to placebo 1
• Beta-3 agonist (mirabegron): Typically preferred before antimuscarinics due to lower cognitive risk 1

Agents with Higher Discontinuation Rates:

• Solifenacin: Lowest discontinuation risk among agents that exceed placebo (NNTH 78) 1
• Fesoterodine: NNTH 33 for discontinuation 1
• Oxybutynin: Highest discontinuation rate (NNTH 16); avoid as first choice 1

Critical Safety Considerations:

Discuss dementia risk with all patients prescribed antimuscarinics. 1 Meta-analyses show association between antimuscarinic use and incident dementia that may be cumulative and dose-dependent. 1

Contraindications and extreme caution situations:

• Absolute contraindication: Narrow-angle glaucoma (unless ophthalmologist approves) 1
• Use with extreme caution: Impaired gastric emptying, urinary retention history 1
• Additional caution: Diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis 1

Common Adverse Effects:

• Antimuscarinics: Dry mouth, constipation, blurred vision (NNTH ranges 6-12 depending on agent) 1
• Mirabegron: Nasopharyngitis, gastrointestinal disorders 1
• Tolterodine: Risk for hallucinations 1

Combination Therapy Approach

Behavioral therapies may be combined with pharmacologic treatment for additive benefit. 1 When combining therapies, add one intervention at a time to assess individual impact. 1 If no improvement occurs with combination therapy, discontinue one or both treatments and pursue alternatives. 1

Treatment Algorithm Summary:

1. Initial: Bladder training + lifestyle modifications (fluid management, caffeine reduction, weight loss if obese) 1

2. If inadequate response: Add beta-3 agonist (mirabegron) OR antimuscarinic (darifenacin/tolterodine preferred) 1

3. If still inadequate: Consider combination of behavioral + pharmacologic therapy 1

4. Refractory cases: Refer for third-line therapies (sacral neuromodulation, onabotulinum toxin-A injections, posterior tibial nerve stimulation) 2

Common Pitfalls to Avoid:

• Don't skip behavioral therapy: Jumping directly to medications misses equally effective, safer first-line options 1
• Don't assume all medications differ in efficacy: They don't—choose based on side effects 1
• Don't ignore cognitive risks in elderly: Antimuscarinics carry dementia risk; prefer beta-3 agonists 1
• Don't prescribe antimuscarinics without screening for contraindications: Check for glaucoma, gastric emptying issues, retention risk 1